Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 5th International Workshop on the Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplant (R-HSCT) took place between October 7-9 in New York, NY, in 2021, exploring research, experiences and evidence discovered since the previous meeting, with talks from leading experts.

Relapse after HSCT 2021

The 5th International Workshop on Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplant
07–09 October 2021 | New York, NY
VJHemOnc avatar

VJHemOnc

@VJHemOnc ·
2 Nov 2117250429020987422

📖 Have you had a chance to read our newest feature article, focusing on BTK inhibitors in CLL and the move beyond covalent inhibition with the emergence of non-covalent agents and BTK degraders?

Click here to check it out:
👉 https://ow.ly/NmxG5101itW

#CLLsm #Leusm #Leukemia

Image for the Tweet beginning: 📖 Have you had a Twitter feed image.
Reply on Twitter 2117250429020987422 Retweet on Twitter 2117250429020987422 4 Like on Twitter 2117250429020987422 3 View Tweet 2117250429020987422

Relapse after HSCT 2021

The 5th International Workshop on Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplant
07–09 October 2021 | New York, NY
The 5th International Workshop on the Biology, Prevention and Treatment of Relapse After Hematopoietic Stem Cell Transplant (R-HSCT) took place between October 7-9 in New York, NY, in 2021, exploring research, experiences and evidence discovered since the previous meeting, with talks from leading experts.
VJHemOnc avatar

VJHemOnc

@VJHemOnc ·
2 Nov 2117250429020987422

📖 Have you had a chance to read our newest feature article, focusing on BTK inhibitors in CLL and the move beyond covalent inhibition with the emergence of non-covalent agents and BTK degraders?

Click here to check it out:
👉 https://ow.ly/NmxG5101itW

#CLLsm #Leusm #Leukemia

Image for the Tweet beginning: 📖 Have you had a Twitter feed image.
Reply on Twitter 2117250429020987422 Retweet on Twitter 2117250429020987422 4 Like on Twitter 2117250429020987422 3 View Tweet 2117250429020987422
Management of relapse after CAR-T in patients with B-cell lymphoma 1:33
Management of relapse after CAR-T in patients with B-cell lymphoma
Peter Dreger • 5 Oct 2021
Challenges of CAR-T therapy for CLL 1:51
Challenges of CAR-T therapy for CLL
Peter Dreger • 5 Oct 2021
Improving virus-specific T-cell therapy 1:29
Improving virus-specific T-cell therapy
Susan Prockop • 5 Oct 2021
Management of relapse post-alloHSCT in patients with B-cell lymphoma 1:56
Management of relapse post-alloHSCT in patients with B-cell lymphoma
Peter Dreger • 5 Oct 2021
The use of viral-specific T-cells post bone marrow transplantation 1:55
The use of viral-specific T-cells post bone marrow transplantation
Susan Prockop • 5 Oct 2021
Management of relapse after CAR-T 3:28
Management of relapse after CAR-T
Michael Bishop • 29 Sep 2021
The use of targeted therapy to prevent relapse post-transplant 2:42
The use of targeted therapy to prevent relapse post-transplant
Mark Levis • 30 Sep 2021
The efficacy of ATO and ATRA for APL 1:49
The efficacy of ATO and ATRA for APL
Mark Levis • 30 Sep 2021
AML risk stratification 2:03
AML risk stratification
Mark Levis • 30 Sep 2021
Patient selection for CAR-T therapy 1:39
Patient selection for CAR-T therapy
Sergio Giralt • 11 Oct 2021
Treating patients relapsed after auto-SCT 4:39
Treating patients relapsed after auto-SCT
Sergio Giralt • 11 Oct 2021
The use of DLI to prevent relapse 0:52
The use of DLI to prevent relapse
Christoph Schmid • 29 Sep 2021
The potential of TCRs for relapse management 1:08
The potential of TCRs for relapse management
Christoph Schmid • 29 Sep 2021
MILs as a source of T-cells for adoptive cellular therapy 0:52
MILs as a source of T-cells for adoptive cellular therapy
Christoph Schmid • 29 Sep 2021
Positioning CAR T-cell therapy for hematological malignancies 1:21
Positioning CAR T-cell therapy for hematological malignancies
Christoph Schmid • 29 Sep 2021
Management of relapse following alloHSCT in patients with AML and MDS 2:47
Management of relapse following alloHSCT in patients with AML and MDS
Thomas Schröder • 5 Oct 2021

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals